Vidofludimus Calcium

5 trials 2 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

2 Sponsors

8 Countries

Phase III

Phase II

Phase III: 2 Phase II: 3

Oversight events:

1 temporary halt across 1 trial

View oversight register →

Indications tested

Relapsing multiple sclerosis 2 Progressive multiple sclerosis 1 Relapsing-remitting multiple sclerosis 1

Sponsors using this IMP

Immunic AG 4 Goethe University Frankfurt 1

All trials

5 total

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with P… Recruiting

2024-514617-35-00 Phase II 6 countries Immunic AG
Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by … Recruiting

2024-516739-29-00 Phase II 4 countries Immunic AG
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu… Ended

2024-514619-88-00 Phase III 4 countries Immunic AG
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu… Ended

2024-514618-11-00 Phase III 4 countries Immunic AG
Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome… Ended

2024-511628-16-00 Phase II 1 country Goethe University Frankfurt

Showing 1–5 of 5 trials

← All drugs A–Z